| Code | CSB-RA003657MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Claseprubart, designed for research applications targeting complement component 1s (C1S). C1S is a serine protease that functions as part of the C1 complex in the classical complement pathway, where it cleaves complement components C2 and C4 to initiate the complement cascade. This proteolytic activity plays a critical role in immune defense, but dysregulated C1S activation contributes to various pathological conditions including autoimmune diseases, antibody-mediated rejection in transplantation, and complement-mediated inflammatory disorders. Aberrant complement activation has been implicated in conditions such as cold agglutinin disease and other complement-driven hemolytic anemias.
Claseprubart is a therapeutic antibody developed to selectively inhibit C1S activity, thereby modulating classical complement pathway activation. This biosimilar provides researchers with a valuable tool for investigating C1S-mediated mechanisms in complement biology, exploring the role of classical pathway activation in disease models, and evaluating potential therapeutic strategies for complement-related disorders. It enables detailed studies of complement regulation and immune-mediated pathologies in controlled laboratory settings.
There are currently no reviews for this product.